US Patent

US8906847 — Prodrug comprising a drug linker conjugate

Method of Use · Assigned to Ascendis Pharma AS · Expires 2031-04-30 · 5y remaining

Vulnerability score 81/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a prodrug composition that includes a biologically active moiety attached to a non-active linker moiety through an amide bond.

USPTO Abstract

The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein -D is an amine containing biologically active moiety; and -L is a non-biologically active linker moiety -L1 represented by formula (I), wherein the dashed line indicates the attachment to the amine of the biologically active moiety and wherein R1, R1a, R2, R2a, R3, R3a, X, X1, X2, X3 have the meaning as indicated in the description and the claims and wherein L1 is substituted with one to four groups L2-Z and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (I) is not replaced by a substituent; wherein L2 is a single chemical bond or a spacer; and Z is a carrier group. The invention also relates to A-L, wherein A is a leaving group, pharmaceutical composition comprising said prodrugs and their use as medicaments.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3982 — Yorvipath
U-3982 — Yorvipath
U-4425 —
U-4425 —
U-4425 —
U-3982 — Yorvipath

Patent Metadata

Patent number
US8906847
Jurisdiction
US
Classification
Method of Use
Expires
2031-04-30
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Ascendis Pharma AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.